E5 murine monoclonal antiendotoxin antibody in gram-negative sepsis: a randomized controlled trial. E5 Study Investigators.

PubWeight™: 2.07‹?› | Rank: Top 2%

🔗 View Article (PMID 10755499)

Published in JAMA on April 05, 2000

Authors

D C Angus1, M C Birmingham, R A Balk, P J Scannon, D Collins, J A Kruse, D R Graham, H V Dedhia, S Homann, N MacIntyre

Author Affiliations

1: Department of Anesthesiology and Critical Care Medicine, and Center for Research on Health Care, University of Pittsburgh, PA 15213, USA. angusdc@anes.upmc.edu

Associated clinical trials:

Bovine Intestinal Alkaline Phosphatase for the Treatment of Patients With Sepsis | NCT00430859

Articles citing this

Randomized, controlled trials, observational studies, and the hierarchy of research designs. N Engl J Med (2000) 19.56

Receptors, mediators, and mechanisms involved in bacterial sepsis and septic shock. Clin Microbiol Rev (2003) 3.70

Infection rate and acute organ dysfunction risk as explanations for racial differences in severe sepsis. JAMA (2010) 2.27

Sepsis: multiple abnormalities, heterogeneous responses, and evolving understanding. Physiol Rev (2013) 1.72

Clinical practice guidelines for hospital-acquired pneumonia and ventilator-associated pneumonia in adults. Can J Infect Dis Med Microbiol (2008) 1.68

Eritoran tetrasodium (E5564) treatment for sepsis: review of preclinical and clinical studies. Expert Opin Drug Metab Toxicol (2011) 1.36

Current Controlled Trials: an opportunity to help improve the quality of clinical research. Curr Control Trials Cardiovasc Med (2000) 1.34

Observational versus experimental studies: what's the evidence for a hierarchy? NeuroRx (2004) 1.23

Animal models of sepsis. Virulence (2013) 1.22

Clinical applications of intravenous immunoglobulins (IVIg)--beyond immunodeficiencies and neurology. Clin Exp Immunol (2009) 1.16

Selective iNOS inhibition for the treatment of sepsis-induced acute kidney injury. Nat Rev Nephrol (2009) 1.14

Novel pharmacologic approaches to the management of sepsis: targeting the host inflammatory response. Recent Pat Inflamm Allergy Drug Discov (2009) 1.14

The EUPHRATES trial (Evaluating the Use of Polymyxin B Hemoperfusion in a Randomized controlled trial of Adults Treated for Endotoxemia and Septic shock): study protocol for a randomized controlled trial. Trials (2014) 1.12

Shiga toxins and the pathophysiology of hemolytic uremic syndrome in humans and animals. Toxins (Basel) (2012) 1.10

Serious adverse events in academic critical care research. CMAJ (2008) 1.08

Preclinical investigations reveal the broad-spectrum neutralizing activity of peptide Pep19-2.5 on bacterial pathogenicity factors. Antimicrob Agents Chemother (2013) 1.06

Phase 1/2 double-blind, placebo-controlled, dose escalation, safety, and pharmacokinetic study of pagibaximab (BSYX-A110), an antistaphylococcal monoclonal antibody for the prevention of staphylococcal bloodstream infections, in very-low-birth-weight neonates. Antimicrob Agents Chemother (2009) 1.05

Harvesting, identification and barrier function of human lung microvascular endothelial cells. Vascul Pharmacol (2010) 1.01

Interleukin 5 is protective during sepsis in an eosinophil-independent manner. Am J Respir Crit Care Med (2012) 1.00

Towards clinical applications of anti-endotoxin antibodies; a re-appraisal of the disconnect. Toxins (Basel) (2013) 0.98

Lymphocytes, apoptosis and sepsis: making the jump from mice to humans. Crit Care (2009) 0.95

Lack of evidence for qualitative treatment by disease severity interactions in clinical studies of severe sepsis. Crit Care (2005) 0.93

Cytokines in the systemic inflammatory response syndrome: a review. HSR Proc Intensive Care Cardiovasc Anesth (2010) 0.93

Pediatric Sepsis - Part I: "Children are not small adults!" Open Inflamm J (2011) 0.87

Immunomodulation in sepsis: the role of endotoxin removal by polymyxin B-immobilized cartridge. Mediators Inflamm (2013) 0.86

Sepsis and septic shock. Nat Rev Dis Prim (2016) 0.85

Does gram-negative bacteraemia occur without endotoxaemia? A meta-analysis using hierarchical summary ROC curves. Eur J Clin Microbiol Infect Dis (2009) 0.84

Dexamethasone improves vascular hyporeactivity induced by LPS in vivo by modulating ATP-sensitive potassium channels activity. Br J Pharmacol (2003) 0.82

Clavanin A improves outcome of complications from different bacterial infections. Antimicrob Agents Chemother (2014) 0.79

A targeted extracorporeal therapy for endotoxemia: the time has come. Crit Care (2007) 0.79

Microbial Recognition and Danger Signals in Sepsis and Trauma. Biochim Biophys Acta (2017) 0.78

The immune response: targets for the treatment of severe sepsis. Int J Inflam (2012) 0.77

New strategy for sepsis: Targeting a key role of platelet-neutrophil interaction. Burns Trauma (2014) 0.77

Endotoxin Elimination in Patients with Septic Shock: An Observation Study. Arch Immunol Ther Exp (Warsz) (2015) 0.77

Efficacy of a novel endotoxin adsorber polyvinylidene fluoride fiber immobilized with (L)-serine ligand on septic pigs. J Zhejiang Univ Sci B (2011) 0.77

New insights into acute lung injury. Vascul Pharmacol (2010) 0.76

Insights and limits of translational research in critical care medicine. Ann Intensive Care (2015) 0.76

A novel role of kukoamine B: Inhibition of the inflammatory response in the livers of lipopolysaccharide-induced septic mice via its unique property of combining with lipopolysaccharide. Exp Ther Med (2015) 0.76

Protective Effects of Huang-Lian-Jie-Du-Tang against Polymicrobial Sepsis Induced by Cecal Ligation and Puncture in Rats. Evid Based Complement Alternat Med (2013) 0.76

Low-dose polymyxin: an option for therapy of Gram-negative sepsis. Innate Immun (2016) 0.75

Abdominal Septic Shock - Endotoxin Adsorption Treatment (ASSET) - endotoxin removal in abdominal and urogenital septic shock with the Alteco® LPS Adsorber: study protocol for a double-blinded, randomized placebo-controlled trial. Trials (2016) 0.75

[Endotoxins. Pathogenetic meaning of sepsis]. Anaesthesist (2003) 0.75

Man is the new mouse: Elective surgery as a key translational model for multi-organ dysfunction and sepsis. J Intensive Care Soc (2015) 0.75

Articles by these authors

(truncated to the top 100)

Standardisation of spirometry. Eur Respir J (2005) 48.20

Definitions for sepsis and organ failure and guidelines for the use of innovative therapies in sepsis. The ACCP/SCCM Consensus Conference Committee. American College of Chest Physicians/Society of Critical Care Medicine. Chest (1992) 47.46

Interpretative strategies for lung function tests. Eur Respir J (2005) 21.50

inhA, a gene encoding a target for isoniazid and ethionamide in Mycobacterium tuberculosis. Science (1994) 11.22

Gemfibrozil for the secondary prevention of coronary heart disease in men with low levels of high-density lipoprotein cholesterol. Veterans Affairs High-Density Lipoprotein Cholesterol Intervention Trial Study Group. N Engl J Med (1999) 9.83

General considerations for lung function testing. Eur Respir J (2005) 7.99

Pharmacodynamics of intravenous ciprofloxacin in seriously ill patients. Antimicrob Agents Chemother (1993) 7.05

Plasma cytokine and endotoxin levels correlate with survival in patients with the sepsis syndrome. Ann Intern Med (1993) 5.46

Treatment of septic shock with the tumor necrosis factor receptor:Fc fusion protein. The Soluble TNF Receptor Sepsis Study Group. N Engl J Med (1996) 5.25

Recombinant human interleukin 1 receptor antagonist in the treatment of patients with sepsis syndrome. Results from a randomized, double-blind, placebo-controlled trial. Phase III rhIL-1ra Sepsis Syndrome Study Group. JAMA (1994) 5.24

Confirmatory interleukin-1 receptor antagonist trial in severe sepsis: a phase III, randomized, double-blind, placebo-controlled, multicenter trial. The Interleukin-1 Receptor Antagonist Sepsis Investigator Group. Crit Care Med (1997) 4.86

Recombinant bactericidal/permeability-increasing protein (rBPI21) as adjunctive treatment for children with severe meningococcal sepsis: a randomised trial. rBPI21 Meningococcal Sepsis Study Group. Lancet (2000) 4.81

Effect of systemic glucocorticoids on exacerbations of chronic obstructive pulmonary disease. Department of Veterans Affairs Cooperative Study Group. N Engl J Med (1999) 4.66

Assembly of an MCP receptor, CheW, and kinase CheA complex in the bacterial chemotaxis signal transduction pathway. Cell (1992) 4.16

A controlled clinical trial of high-dose methylprednisolone in the treatment of severe sepsis and septic shock. N Engl J Med (1987) 3.89

Mutations in the gene encoding for the beta 2-adrenergic receptor in normal and asthmatic subjects. Am J Respir Cell Mol Biol (1993) 3.50

Sepsis syndrome: a valid clinical entity. Methylprednisolone Severe Sepsis Study Group. Crit Care Med (1989) 3.41

The relation of pneumothorax and other air leaks to mortality in the acute respiratory distress syndrome. N Engl J Med (1998) 3.40

Von Hippel-Lindau disease maps to the region of chromosome 3 associated with renal cell carcinoma. Nature (1988) 3.27

Relation of gemfibrozil treatment and lipid levels with major coronary events: VA-HIT: a randomized controlled trial. JAMA (2001) 3.12

Hyperbaric oxygen therapy for necrotizing fasciitis reduces mortality and the need for debridements. Surgery (1990) 2.91

Sepsis: a new hypothesis for pathogenesis of the disease process. Chest (1997) 2.84

Fibrosing alveolitis in patients with rheumatoid arthritis as assessed by high resolution computed tomography, chest radiography, and pulmonary function tests. Thorax (2001) 2.74

Preliminary evaluation of recombinant amino-terminal fragment of human bactericidal/permeability-increasing protein in children with severe meningococcal sepsis. Lancet (1997) 2.71

A second large controlled clinical study of E5, a monoclonal antibody to endotoxin: results of a prospective, multicenter, randomized, controlled trial. The E5 Sepsis Study Group. Crit Care Med (1995) 2.48

Investigation of the chronic pulmonary effects of low-dose oral methotrexate in patients with rheumatoid arthritis: a prospective study incorporating HRCT scanning and pulmonary function tests. Rheumatology (Oxford) (2002) 2.38

Relationship between plasma levels of lipopolysaccharide (LPS) and LPS-binding protein in patients with severe sepsis and septic shock. J Infect Dis (1999) 2.32

Rapid differentiation of bovine and human tubercle bacilli based on a characteristic mutation in the bovine pyrazinamidase gene. J Clin Microbiol (1997) 2.18

Differential incorporation of CD45, CD80 (B7-1), CD86 (B7-2), and major histocompatibility complex class I and II molecules into human immunodeficiency virus type 1 virions and microvesicles: implications for viral pathogenesis and immune regulation. J Virol (2001) 1.97

Activities of ciprofloxacin and ofloxacin against rapidly growing mycobacteria with demonstration of acquired resistance following single-drug therapy. Antimicrob Agents Chemother (1990) 1.96

Oxygen-dependent cleavage of DNA by the 1,10-phenanthroline . cuprous complex. Inhibition of Escherichia coli DNA polymerase I. J Biol Chem (1979) 1.91

Development of a population pharmacokinetic model and optimal sampling strategies for intravenous ciprofloxacin. Antimicrob Agents Chemother (1993) 1.88

Severe soft-tissue injury following intravenous infusion of phenytoin. Patient and drug administration risk factors. Arch Intern Med (1988) 1.82

Germ-line mutations in the von Hippel-Lindau tumor-suppressor gene are similar to somatic von Hippel-Lindau aberrations in sporadic renal cell carcinoma. Am J Hum Genet (1994) 1.80

Fusion of cationic liposomes with mammalian cells occurs after endocytosis. Biochim Biophys Acta (1995) 1.67

The efficacy of SNOMED, Read Codes, and UMLS in coding ambulatory family practice clinical records. Proc AMIA Annu Fall Symp (1996) 1.65

Safety and potential efficacy of an aerosolized surfactant in human sepsis-induced adult respiratory distress syndrome. JAMA (1994) 1.64

The initial effects of a cervical spine manipulative physiotherapy treatment on the pain and dysfunction of lateral epicondylalgia. Pain (1996) 1.56

Cleavage of deoxyribonucleic acid by the 1,10-phenanthroline-cuprous complex. Hydrogen peroxide requirement and primary and secondary structure specificity. Biochemistry (1981) 1.52

An investigation of the interrelationship between manipulative therapy-induced hypoalgesia and sympathoexcitation. J Manipulative Physiol Ther (1998) 1.47

Medical effectiveness of esophageal balloon pressure manometry in weaning patients from mechanical ventilation. Crit Care Med (1995) 1.43

Sleep apnea and the Arnold-Chiari malformation. Am Rev Respir Dis (1985) 1.42

The VA HDL intervention trial: clinical implications. Eur Heart J (2000) 1.41

Prognostic factors in sepsis: the cold facts. Crit Care Med (1992) 1.40

Emergence of ciprofloxacin resistance in nosocomial methicillin-resistant Staphylococcus aureus isolates. Resistance during ciprofloxacin plus rifampin therapy for methicillin-resistant S aureus colonization. Arch Intern Med (1990) 1.39

Acceptance of HIV-1 education & voluntary counselling/testing by & seroprevalence of HIV-1 among, pregnant women in rural south India. Indian J Med Res (2007) 1.39

Continuous infusion versus intermittent administration of ceftazidime in critically ill patients with suspected gram-negative infections. Antimicrob Agents Chemother (1996) 1.29

Nasogastric and nasoenteric intubation. Crit Care Clin (1992) 1.29

Chylothorax review. Crit Care Med (1985) 1.27

Evaluation of a CD5-specific immunotoxin for treatment of acute graft-versus-host disease after allogeneic marrow transplantation. Blood (1996) 1.27

Methemoglobinemia induced by topical anesthesia: a case report and review. Am J Med Sci (1999) 1.27

Nosocomial meningitis due to Citrobacter diversus in neonates: new aspects of the epidemiology. J Infect Dis (1984) 1.26

Reduction in stroke with gemfibrozil in men with coronary heart disease and low HDL cholesterol: The Veterans Affairs HDL Intervention Trial (VA-HIT). Circulation (2001) 1.25

Campylobacter pyloridis is unique: GCLO-2 is an ordinary campylobacter. Lancet (1985) 1.23

Epidemic nosocomial meningitis due to Citrobacter diversus in neonates. J Infect Dis (1981) 1.23

Epidemic neonatal gentamicin-methicillin--resistant Staphylococcus aureus infection associated with nonspecific topical use of gentamicin. J Pediatr (1980) 1.21

Reproduction of porcine proliferative enteropathy with pure cultures of ileal symbiont intracellularis. Infect Immun (1993) 1.19

Demonstration of a new intracellular antigen in porcine intestinal adenomatosis and hamster proliferative ileitis. Vet Microbiol (1985) 1.16

Does footprint depth correlate with foot motion and pressure? J R Soc Interface (2013) 1.15

Atypical mycobacterial infection of soft tissue associated with use of a hot tub. A case report. J Bone Joint Surg Am (1986) 1.14

Citrobacter diversus brain abscess and meningitis in neonates. JAMA (1981) 1.14

Toxic shock syndrome associated with surgical wound infections. JAMA (1982) 1.13

Linezolid in the treatment of osteomyelitis: results of compassionate use experience. Infection (2004) 1.13

Area under the inhibitory curve and a pneumonia scoring system for predicting outcomes of vancomycin therapy for respiratory infections by Staphylococcus aureus. Am J Health Syst Pharm (2000) 1.12

Blood transfusion requirement prediction in patients undergoing primary total hip and knee arthroplasty. Transfus Med (2007) 1.12

Limitations and advantages of the ejection fraction for defining high risk after acute myocardial infarction. Am J Cardiol (1986) 1.11

Registration of dynamic contrast-enhanced MRI using a progressive principal component registration (PPCR). Phys Med Biol (2007) 1.11

Laparoscopic appendectomy for simple and perforated appendicitis in children: the procedure of choice? J Pediatr Surg (2000) 1.11

Fate of cationic liposomes and their complex with oligonucleotide in vivo. Biochim Biophys Acta (1996) 1.10

Common variants in the gene encoding ATP-binding cassette transporter 1 in men with low HDL cholesterol levels and coronary heart disease. Atherosclerosis (2001) 1.10

Collaborative meta-analysis of individual participant data from observational studies of Lp-PLA2 and cardiovascular diseases. Eur J Cardiovasc Prev Rehabil (2007) 1.10

Double-blind study of endotracheal tobramycin in the treatment of gram-negative bacterial pneumonia. The Endotracheal Tobramycin Study Group. Antimicrob Agents Chemother (1990) 1.08

New mouse model for polycystic kidney disease with both recessive and dominant gene effects. Kidney Int (1995) 1.08

Mononuclear cell fraction carrying Herpesvirus saimiri in persistently infected squirrel monkeys. J Natl Cancer Inst (1976) 1.07

Cutaneous inflammation caused by inadvertent intradermal administration of DTP instead of PPD. Am J Public Health (1981) 1.06

Economic impact of increased clinical intervention rates in community pharmacy. A randomised trial of the effect of education and a professional allowance. Pharmacoeconomics (2000) 1.06

Effect of pairing scanning training with block design training in the remediation of perceptual problems in left hemiplegics. J Clin Neuropsychol (1983) 1.05

Research design and mental practice. J Sports Sci (1996) 1.05

Mathematical examination of dual individualization principles (II): The rate of bacterial eradication at the same area under the inhibitory curve is more rapid for ciprofloxacin than for cefmenoxime. Ann Pharmacother (1994) 1.05

Functional significance of variation in bryophyte canopy structure. Am J Bot (2001) 1.04

An autopsy-based study of diagnostic errors in geriatric and nongeriatric adult patients. Arch Intern Med (1989) 1.04

Pneumothorax detection using computerised analysis of breath sounds. Med Biol Eng Comput (2002) 1.03

Retrieval of an aspirated bullet fragment by flexible bronchoscopy in a mechanically ventilated patient. Chest (1993) 1.02

Streptococcal wound infections caused by a vaginal carrier. JAMA (1982) 1.02

Raised pulmonary artery pressures measured with Doppler echocardiography in rheumatoid arthritis patients. Rheumatology (Oxford) (2000) 1.01

Effect of race on survival following in-hospital cardiopulmonary resuscitation. J Fam Pract (1995) 1.01

Arterial catheterization. Crit Care Clin (1992) 1.01

Predictors of progression of HRCT diagnosed fibrosing alveolitis in patients with rheumatoid arthritis. Ann Rheum Dis (2002) 1.01

Significance of blood lactate levels in critically ill patients with liver disease. Am J Med (1987) 1.01

Acute stridor due to an upper tracheal membrane following endotracheal intubation. Eur Respir J (1999) 1.00

Pneumothorax detection using pulmonary acoustic transmission measurements. Med Biol Eng Comput (2002) 1.00

Indwelling small pleural catheter needle thoracentesis in the management of large pleural effusions. Chest (1997) 0.99

Pathogenesis and treatment of the adult respiratory distress syndrome. Arch Intern Med (1996) 0.98

Identification of Mycoplasma fermentans in synovial fluid samples from arthritis patients with inflammatory disease. J Clin Microbiol (2000) 0.98

Minimally invasive and surgical management strategies tailored to the severity of acute diverticulitis. Br J Surg (2013) 0.98

Products of DNA cleavage by the 1,10-phenanthroline-copper complex. Inhibitors of Escherichia coli DNA polymerase I. J Biol Chem (1982) 0.97

Estrogen and gastrointestinal malignancy. Mol Cell Endocrinol (2009) 0.97

Treatment of hospitalized patients with complicated gram-positive skin and skin structure infections: two randomized, multicentre studies of quinupristin/dalfopristin versus cefazolin, oxacillin or vancomycin. Synercid Skin and Skin Structure Infection Group. J Antimicrob Chemother (1999) 0.97

Gut mucosal-arterial Pco2 gradient as an indicator of splanchnic perfusion during systemic hypo- and hypercapnia. Crit Care Med (1999) 0.97

Prediction of late mortality after myocardial infarction from variables measured at different times during hospitalization. Am J Cardiol (1984) 0.97